Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 29, 2017
Reporting Period: Events occurring on December 29, 2017, with transaction closing on January 2, 2018.
The Company entered into a material definitive agreement to raise capital via a convertible promissory note and executed a new consulting agreement. Proceeds from the financing were utilized to repay existing debt.
Key Financial Metrics and Agreements
Convertible Note Financing
- Principal Amount: $532,434.65
- Purchase Price: $507,080.62 (reflecting an Original Issue Discount of $25,354.03)
- Interest Rate: 8% per annum (payable in shares upon conversion)
- Maturity Date: December 29, 2018
- Conversion Price: 60% of the lowest closing bid price of the prior 10 trading days (reduces to 50% if trading is restricted by DTC).
- Use of Proceeds: Full repayment of outstanding debt to Delafield Investments Limited.
Consulting Agreement
- Counterparty: Alan Morell
- Term: One year
- Compensation Structure:
- Hourly fee up to $71,250.
- Fixed fee of $9,772 for marketing materials.
- Upfront equity: 500,000 restricted shares (plus up to 750,000 additional shares at Company discretion).
- Performance bonus: 6% of the value of business collaborations or strategic transactions introduced by the consultant.
Material Changes and Debt Obligations
The filing reports the creation of a new direct financial obligation (the Note) and the extinguishment of prior debt owed to Delafield Investments Limited. The Note includes significant prepayment penalties and default provisions that could materially increase the Company's liabilities:
- Prepayment Penalties: Ranging from 130% to 150% of the face amount plus accrued interest, depending on the timing of prepayment (within 60, 120, or 180 days).
- Default Interest: Increases to 24% per annum upon an event of default.
- Principal Accretion on Default:
- 20% increase if the Company loses its bid price.
- 50% increase if delisted, trading is suspended for >10 days, or reporting obligations are failed.
- 10% increase if principal and interest are not paid on the maturity date.
- Conversion Penalties: Daily penalties of $250 (days 4-9) and $500 (day 10+) for failure to issue shares upon conversion notice.
Outlook, Risks, and Contingencies
Risks and Contingencies:
- Dilution Risk: The conversion discount (60% of market price) and potential reduction to 50% create significant dilution risk for existing shareholders.
- Liquidity Risk: High prepayment premiums and potential principal accretion on default events could strain future cash flows.
- Compliance Risk: Failure to maintain reporting obligations or stock quotation status triggers severe financial penalties and conversion price adjustments.
- Equity Issuance: The consulting agreement involves the issuance of up to 1.25 million shares, subject to discretion and performance metrics.
Management Commentary: The filing does not provide forward-looking financial guidance or management commentary beyond the description of the executed agreements.
Investor Verification Checklist
- Verify the current outstanding share count to assess the dilution impact of the 500,000+ consulting shares and potential note conversion.
- Confirm the status of the debt repayment to Delafield Investments Limited.
- Monitor the Company's stock bid price and trading status on OTC Markets to evaluate potential conversion price adjustments and default triggers.
- Review the Company's ability to meet the 60-day share reserve requirement (3x the number of shares issuable upon conversion) to avoid a 10% increase in the conversion discount.
- Check for any subsequent filings regarding the issuance of shares for the consulting agreement or the conversion of the Note.